Cell Therapeutics Files For SPA On New Xyotax Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Study will narrow enrollment for Novartis-partnered compound to women with normal estrogen levels, CEO tells "The Pink Sheet" DAILY.